Search

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

Meeting chairs, Carlo Balduini and Anna Falanga

The meeting was well attended by more than 100 participants coming from over 20 different countries

Delegate: Great meeting.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Read more

Curriculum-Exam Committee call for interest

The aim of the Curriculum-Exam Committee is to promote harmonization in hematology training and education in Europe and beyond. It does this by offering tools and programs, such as the European Hematology Curriculum and the European Hematology Exam.

Read more

Reducing bureaucracy in clinical trials: now is the time!

Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.

Read more